MOMA Therapeutics is a clinical-stage, next-generation precision medicine company dedicated to targeting highly dynamic proteins that underlie human disease via a small molecule approach, utilizing its proprietary KNOMATIC platform. The platform was designed to exploit key vulnerabilities inherent to all dynamic proteins, namely their dependence on well-coordinated, stepwise changes in protein conformation. By focusing on genetically validated targets with high translation potential MOMA is rapidly advancing its pipeline toward responses in the clinic. In January 2024, MOMA announced a five-year discovery collaboration with Roche focused on critical cancer dependencies.
We are unapologetically scientific, and we know this will help us achieve our mission to get new medicines to people in need. We’ve removed the bureaucracy and believe having a teammate’s back is critical to our success. You see, MOMA isn’t your typical biotech company. We are drug discovery professionals, industry specialists and scientific experts. More importantly, we’re collectively unstoppable.
Company Details
- Employees
- 60
- Founded
- -
- Address
- 20 Acorn Park Drive,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.momatx.com
- HQ
- Cambridge , Massachusetts
Moma Therapeutics Questions
Moma Therapeutics's website is http://www.momatx.com
Moma Therapeutics's LinkedIn profile is https://www.linkedin.com/company/momatx
Moma Therapeutics has
60 employees.
View email and phone details for 60
employees at Moma Therapeutics.
Moma Therapeutics's industry is
Biotechnology Research
Moma Therapeutics's top competitors are
Orna Therapeutics,
Rapport Therapeutics,
Beam Therapeutics,
Kymera Therapeutics,
Vertex Pharmaceuticals,
Tango Therapeutics,
Relay Therapeutics,
Tessera Therapeutics,
Nested Therapeutics,
Remix Therapeutics.
Moma Therapeutics's categories are Biotechnology Research
Moma Therapeutics's founding year is 2020
